Diplomat Pharmacy (DPLO) Downgraded to Underperform at Robert W. Baird

Robert W. Baird cut shares of Diplomat Pharmacy (NYSE:DPLO) from a neutral rating to an underperform rating in a research note released on Wednesday morning, MarketBeat reports. Robert W. Baird currently has $10.00 price objective on the stock, down from their prior price objective of $22.00.

Other analysts have also recently issued reports about the stock. ValuEngine raised shares of Diplomat Pharmacy from a sell rating to a hold rating in a research note on Tuesday, October 23rd. Zacks Investment Research raised shares of Diplomat Pharmacy from a sell rating to a hold rating in a research note on Tuesday. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and six have given a buy rating to the company. The stock presently has an average rating of Hold and a consensus price target of $25.20.

DPLO traded up $0.28 during trading on Wednesday, hitting $15.08. The company’s stock had a trading volume of 1,832,544 shares, compared to its average volume of 765,330. The company has a current ratio of 0.91, a quick ratio of 0.63 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $1.51 billion, a PE ratio of 17.95 and a beta of 0.95. Diplomat Pharmacy has a one year low of $13.31 and a one year high of $28.74.

Diplomat Pharmacy (NYSE:DPLO) last announced its quarterly earnings data on Tuesday, November 6th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.22 by ($0.21). The firm had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.42 billion. Diplomat Pharmacy had a return on equity of 5.33% and a net margin of 0.04%. The business’s revenue for the quarter was up 22.0% on a year-over-year basis. During the same period last year, the company earned $0.01 earnings per share. Equities analysts forecast that Diplomat Pharmacy will post 0.83 earnings per share for the current fiscal year.

In related news, Director Philip R. Hagerman sold 57,500 shares of the firm’s stock in a transaction on Tuesday, September 11th. The shares were sold at an average price of $19.21, for a total transaction of $1,104,575.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Philip R. Hagerman sold 209,367 shares of the firm’s stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $19.07, for a total transaction of $3,992,628.69. The disclosure for this sale can be found here. Company insiders own 24.70% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of DPLO. FMR LLC grew its stake in Diplomat Pharmacy by 154.4% during the second quarter. FMR LLC now owns 2,798,440 shares of the company’s stock valued at $71,528,000 after acquiring an additional 1,698,341 shares in the last quarter. Frontier Capital Management Co. LLC grew its stake in Diplomat Pharmacy by 84.1% during the third quarter. Frontier Capital Management Co. LLC now owns 3,535,217 shares of the company’s stock valued at $68,619,000 after acquiring an additional 1,614,645 shares in the last quarter. Janus Henderson Group PLC grew its stake in Diplomat Pharmacy by 30.7% during the second quarter. Janus Henderson Group PLC now owns 5,385,168 shares of the company’s stock valued at $137,645,000 after acquiring an additional 1,265,271 shares in the last quarter. Victory Capital Management Inc. grew its stake in Diplomat Pharmacy by 17,568.5% during the second quarter. Victory Capital Management Inc. now owns 1,239,442 shares of the company’s stock valued at $31,679,000 after acquiring an additional 1,232,427 shares in the last quarter. Finally, Rice Hall James & Associates LLC purchased a new position in Diplomat Pharmacy during the second quarter valued at $20,932,000. 82.05% of the stock is owned by institutional investors.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Recommended Story: What is a Swap?

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply